Leukemia Clinical Trials in Arizona

Showing 201-220 of 670 trials

ACTIVE_NOT_RECRUITINGPHASE1/PHASE231 miles

A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

NCT03162536

This study aims to evaluate the safety, tolerability, pharmacodynamic, and pharmacokinetic (PK) of nemtabrutinib (formerly ARQ 531) tablets in selected participants with relapsed or refractory hematologic malignancies. No formal hypothesis testing will be performed for this study.

Lymphoma, B-CellSmall Lymphocytic LymphomaChronic Lymphocytic Leukemia+6 more

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)190 participantsStarted Jun 2017

Scottsdale, Arizona, United States • Los Angeles, California, United States • Denver, Colorado, United States +7 more locations

COMPLETEDPHASE1/PHASE231 miles

Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer

NCT01737502

This phase I/II trial studies the side effects and best dose of auranofin when given together with sirolimus and to see how well it works in treating patients with lung cancer that has spread or other places in the body and cannot be cured or controlled by treatment or has come back after a period of time during which the cancer could not be detected. Auranofin and sirolimus may stop or slow the growth of lung cancer.

Extensive Stage Small Cell Lung CarcinomaLung AdenocarcinomaRecurrent Non-Small Cell Lung Carcinoma+5 more

Mayo Clinic29 participantsStarted May 2014

Scottsdale, Arizona, United States • Jacksonville, Florida, United States

PreviousPage 11 of 34Next

A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer

Leukemia Trials in Other Cities

Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancreas Cancer

A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL

A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)

DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia

Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers

Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer

A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)

Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Other Conditions in Arizona